Inovio receives NIH funding for its dMAb® AMR technology
Inovio Pharmaceuticals and The Wistar Institute have received a $4.6 million NIH grant in support of innovative research to tackle antimicrobial resistance employing Inovio's DNA-encoded monoclonal antibodies (dMAb®) platform. September 17, 2019